Trials / Completed
CompletedNCT00137020
Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder
A Multi-Center Study to Examine The Clinical Effects of Cross Titration of Antipsychotics With Ziprasidone in Subjects With Schizophrenia or Schizoaffective Disorder
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 294 (planned)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective is to compare effectiveness of ziprasidone treatment to current treatments (haloperidol, olanzapine or risperidone) measured by change in Brief Psychiatric Rating Scale (BPRS) scores versus baseline
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ziprasidone |
Timeline
- Start date
- 2004-11-01
- Completion
- 2006-04-01
- First posted
- 2005-08-29
- Last updated
- 2021-02-21
Locations
27 sites across 9 countries: Egypt, Greece, Jordan, Kuwait, Lebanon, Saudi Arabia, South Africa, Turkey (Türkiye), United Arab Emirates
Source: ClinicalTrials.gov record NCT00137020. Inclusion in this directory is not an endorsement.